<DOC>
	<DOCNO>NCT03058562</DOCNO>
	<brief_summary>The study investigate effect safety single-dose ABX-1431 HCl tic symptom Tourette Syndrome . During course study patient receive study drug placebo .</brief_summary>
	<brief_title>A Study Evaluate Effects ABX-1431 Patients With Tourette Syndrome</brief_title>
	<detailed_description>This single dose , double-blind , randomize , placebo-controlled , cross-over study . This study ass single dose effect ABX-1431 HCl tic symptom Tourette Syndrome . All patient undergo screen visit enrollment criterion . Eligible patient treat single dose ABX-1431 HCl placebo follow efficacy , safety pharmacokinetics assessment . After washout period 1-3 week , patient undergo identical procedure treatment . This study enroll 20 patient diagnosis Tourette Syndrome OR chronic motor tic disorder .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Tourette Syndrome</mesh_term>
	<mesh_term>Tic Disorders</mesh_term>
	<mesh_term>Tics</mesh_term>
	<criteria>Principal Patient male female age 18 65 year age Screening Visit . Patient diagnosis Tourette Syndrome OR chronic motor tic disorder define Diagnostic Statistical Manual Mental Disorders , Fifth Edition ( DSM5 ) criterion . Patient 's Yale Global Tic Severity Scale ( YGTSS ) total tic subscale ( TTS ) result must â‰¥ 18 ( Range 050 ) Screening Visit . Patients take daily medication symptom Tourette Syndrome [ e.g . neuroleptic ( e.g . aripiprazole , risperidone ) selective serotonin reuptake inhibitor ( e.g . fluoxetine ) ] must stable dose medication least 30 day Screening Visit must expect remain stable dose study . Principal Patient take potent cytochrome P450 3A4/5 inducer [ e.g . carbamazepine , oxcarbazine , rifampin , St. John 's Wort ( Hypericum perforatum ) , phenytoin ] . Patient take strong P450 3A4/5 inhibitor include atazanavir , bocepravir , clarithromycin , grapefruit juice , indinavir , itraconazole , ketoconazole , nefazodone , nelfinavir , posaconazole , ritonavir , saquinavir , telithromycin , voriconazole . Patients diagnosis psychiatric comorbidity ( obsessive compulsive disorder , attention deficit hyperactivity disorder ) OR generalize anxiety disorder , depression posttraumatic stress disorder unstable require alteration therapy exclude . Patients past history psychosis schizophrenia time exclude . Patients stable OCD ADHD require alteration therapy may enrol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>